ReShape Q3 revenue down 24.5% to $2.8M; non-GAAP adj. EBITDA loss $4.3M

Vyome Holdings, Inc

2022-Q3 EPS reported -$1.47 revenue$8,130,000

Revenue $2.8M for Q3 2022, down 24.5% YoY from $3.7M due to European sales decline.
Gross margin improved to 75.1% from 57.6%, driven by higher domestic sales mix and cost cuts.
Non-GAAP adjusted EBITDA loss widened to $4.3M from $3.6M in Q3 2021.
Cash and equivalents $6.1M as of Sep 30, 2022; company remains debt-free.
Appointed new CEO Paul F. Hickey in August; received FDA 510(k) clearance for GIBI HD tube.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Vyome Holdings, Inc reported financial results for the three and nine months ended September 30, 2022.

Period: the three and nine months ended September 30, 2022
Result: reported results

Exact text from the filing

ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial and operating results for the third quarter ended September 30, 2022 and provided a corporate strategic update.

View on SEC.gov

Browse all earnings releases →

Vyome Holdings, Inc filing history →

Source: SEC EDGAR

accession 0001558370-22-017827

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.